Varlilumab (anti-CD27)

Synonyms: CDX-1127 (anti-CD27)
Varlilumab (CDX-1127)(anti-CD27)是一种激动剂抗 CD27 单克隆抗体,能促进 T 细胞扩增并激活免疫反应,具有抗肿瘤活性,可用于血液系统恶性肿瘤和实体瘤的研究。
产品编号: MS-W58070 纯度: 99.68% CAS No.: 1393344-72-3
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
询价
10mg
询价
询价

产品描述

Varlilumab (CDX-1127)(anti-CD27)是一种激动剂抗 CD27 单克隆抗体,能促进 T 细胞扩增并激活免疫反应,具有抗肿瘤活性,可用于血液系统恶性肿瘤和实体瘤的研究。

生物实验数据

生物活性 Varlilumab (CDX-1127) (anti-CD27) is an agonist anti-CD27 monoclonal antibody that promotes T cell expansion and activates immune responses, exhibits antitumor activity, and can be used for research on hematologic malignancies and solid tumors.
IC50 & Target

TNFRSF7/CD27

体内研究
(In Vivo)

Varlilumab (anti-CD27) (300 μg; 腹腔注射; 两次) 在接种 E.G7 肿瘤的 hCD27+/+mCD27-/-小鼠中,可延长小鼠的中位生存期且有较高的治愈率。

Clinical Trial
NCT NumberSponsorConditionStart DatePhase
NCT02335918Celldex Therapeutics|Bristol-Myers Squibb
Squamous Cell Carcinoma of the Head and Neck (SCCHN)|Ovarian Carcinoma-Enrollment Completed|Colorectal Cancer (CRC)-Enrollment Completed|Renal Cell Carcinoma (RCC) (Phase ll Only)|Glioblastoma (GBM) (Phase ll Only)-Enrollment Completed
2015-01PHASE1|PHASE2
NCT02386111Celldex Therapeutics
Carcinoma, Renal Cell|Kidney Diseases|Kidney Neoplasms|Urogenital Neoplasms|Urologic Diseases|Urologic Neoplasms|Neoplasms|Neoplasms by Histologic Type|Clear-cell Metastatic Renal Cell Carcinoma
2015-05PHASE1
NCT03038672National Cancer Institute (NCI)
ALK-Positive Large B-Cell Lymphoma|Diffuse Large B-Cell Lymphoma Activated B-Cell Type|Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation|Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type|Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|EBV-Positive Mucocutaneous Ulcer|HHV8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|High Grade B-Cell Lymphoma With MYC and BCL2 and+or BCL6 Rearrangements|High Grade B-Cell Lymphoma, Not Otherwise Specified|Intravascular Large B-Cell Lymphoma|Large B-Cell Lymphoma With 11q Aberration|Large B-Cell Lymphoma With IRF4 Rearrangement|Plasmablastic Lymphoma|Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System|Primary Effusion Lymphoma|Recurrent B-Cell Non-Hodgkin Lymphoma|Recurrent Burkitt Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Gray-Zone Lymphoma|Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements|Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements|Recurrent Lymphomatoid Granulomatosis|Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type|Recurrent Primary Mediastinal Large B-Cell Lymphoma|Recurrent T-Cell+Histiocyte-Rich Large B-Cell Lymphoma|Refractory B-Cell Non-Hodgkin Lymphoma|Refractory Burkitt Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Gray-Zone Lymphoma|Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements|Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements|Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type|Refractory Primary Mediastinal Large B-Cell Lymphoma|Refractory T-Cell+Histiocyte-Rich Large B-Cell Lymphoma
2018-12-21PHASE2
性状 液体
颜色 Colorless to light yellow

化学信息

CAS No. 1393344-72-3
别名 CDX-1127 (anti-CD27)

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Shipping with dry ice.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础